ARTI<u>CLE IN PRESS</u>

Clinica Chimica Acta xxx (2013) xxx-xxx

Contents lists available at SciVerse ScienceDirect



Clinica Chimica Acta



40

journal homepage: www.elsevier.com/locate/clinchim

1 Invited critical review

9

Xiao-hua Yu^a, Yu-chang Fu^c, Da-Wei Zhang^d, Kai Yin^{b,*}, Chao-ke Tang^{a,b,**} Q13

^a Life Science Research Center, University of South China, Hengyang, Hunan 421001, China

- ^b Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang, Hunan 421001, China
- ^c Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294-0012, USA
- ^d Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Alberta T6G 2S2, Canada
 - ARTICLE INFO

Article history:

Keywords:

CD36

SR-A

ACAT1

nCEH

ABCA1

ABCG1

SR-BI

Macrophages Foam cells

Received 25 April 2013

Accepted 6 June 2013

Available online xxxx

Received in revised form 4 June 2013

ABSTRACT

Atherosclerosis is a chronic disease characterized by the deposition of excessive cholesterol in the arterial intima. 28 Macrophage foam cells play a critical role in the occurrence and development of atherosclerosis. The generation of 29 these cells is associated with imbalance of cholesterol influx, esterification and efflux. CD36 and scavenger receptor 30 class A (SR-A) are mainly responsible for uptake of lipoprotein-derived cholesterol by macrophages. Acyl coen- 31 zyme A:cholesterol acyltransferase-1 (ACAT1) and neutral cholesteryl ester hydrolase (nCEH) regulate cholesterol 32 esterification. ATP-binding cassette transporters A1(ABCA1), ABCG1 and scavenger receptor BI (SR-BI) play crucial 33 roles in macrophage cholesterol export. When inflow and esterification of cholesterol increase and/or its outflow 34 decrease, the macrophages are ultimately transformed into lipid-laden foam cells, the prototypical cells in the 35 atherosclerotic plaque. The aim of this review is to describe what is known about the mechanisms of cholesterol 36 uptake, esterification and release in macrophages. An increased understanding of the process of macrophage 37 foam cell formation will help to develop novel therapeutic interventions for atherosclerosis. 38

© 2013 The Authors. Published by Elsevier B.V. All rights reserved. 39

43 42

0 10

11

12

13

14

16

18

20

21

22

23

24

2526

27

Q219

Contents 45

-1		
16	Introduction	0
17	2. Cholesterol uptake	0
18	2.1. CD36	0
9	2.2. SR-A	0
50	B. Cholesterol esterification	0
51	3.1. ACAT1	0
52	3.2. nCEH	0
53	l. Cholesterol efflux	0
54	4.1. ABCA1	0
55	4.2. ABCG1	0
56	4.3. SR-BI	0
57	5. Conclusion and future directions	0
58	Acknowledgment	0
59	References	0

60

Abbreviations: ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; SR-BI, scavenger receptor BI; SR-A, scavenger receptor class A; ACAT1, acyl coenzyme A:cholesterol acyltransferase-1; nCEH, neutral cholesteryl ester hydrolase; ox-LDL, oxidized low-density lipoprotein; HDL, high-density lipoprotein; apoA-I, apolipoprotein A-I; LDLR, low-density lipoprotein receptor; apoE, apolipoprotein E; CE, cholesterol ester; FC, free cholesterol; LXR, liver X receptor; RXR, retinoid X receptor; PPAR-y, peroxisome proliferator-activated receptor-y; ERK1/2, extracellular signal-regulated kinases 1 and 2; PPREs, PPAR response elements; PKB, protein kinase B; PKC, protein kinase C; TGF-₃, transforming growth factor-B; MAPK, mitogen-activated protein kinase; RCT, reverse cholesterol transport; PI3K, phosphatidylinositol 3-kinase; AGE, advanced glycation end products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Corresponding author. Tel./fax: +86 734 8281852.

** Correspondence to: Institute of Cardiovascular Research, University of South China, Hengyang, Hunan 421001, China. Tel./fax: +86 734 8281853.

E-mail addresses: kaiyinby@yahoo.com.cn (K. Yin), tchaoke@yahoo.com.cn (C. Tang).

0009-8981/\$ - see front matter © 2013 The Authors. Published by Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.cca.2013.06.006

Please cite this article as: Yu X, et al, Foam cells in atherosclerosis, Clin Chim Acta (2013), http://dx.doi.org/10.1016/j.cca.2013.06.006

2

ARTICLE IN PRESS

X. Yu et al. / Clinica Chimica Acta xxx (2013) xxx-xxx

61 **1. Introduction**

Atherosclerotic diseases are the major causes of mortality and 62 63 morbidity in the world. Formation of macrophage foam cells in the intima is a major hallmark of early stage atherosclerotic lesions. 64 Uncontrolled uptake of oxidized low-density lipoprotein (ox-LDL), ex-65 cessive cholesterol esterification and/or impaired cholesterol release 66 67 result in accumulation of cholesterol ester (CE) stored as cytoplasmic lipid droplets and subsequently trigger the formation of foam cells. 68 69 Scavenger receptors (SRs), CD36 and SR class A (SR-A) are the principal receptors responsible for the binding and uptake of ox-LDL in mac-70 rophages [1]. Acyl coenzyme A:cholesterol acyltransferase-1 (ACAT1) 71and neutral cholesteryl ester hydrolase (nCEH) play a critical role in 72 cholesterol esterification [2]. ATP-binding cassette (ABC) transporter 73 A1(ABCA1), ABCG1 and scavenger receptor-BI (SR-BI) mediate cho-74 lesterol export from macrophages [3]. This review focuses on the 75 recent developments in our knowledge of the roles and regulation of 76 these receptors, enzymes and transporters in the formation of macro-77 phage foam cells. 78

79 2. Cholesterol uptake

80 Cholesterol uptake is a pathway by which extracellular modified LDL are ingested by macrophages via receptors-mediated phagocyto-81 sis and pinocytosis. SRs such as SR-A and CD36 have been implicated 82 in this process. In vitro studies have shown that CD36 and SR-A ac-83 count for 75% to 90% of ox-LDL internalization by macrophages, 84 85 whereas other SRs cannot compensate for their absence [4]. Thus, CD36 and SR-A are the most important receptors responsible for the 86 uptake of modified lipoproteins by macrophages. 87

88 2.1. CD36

CD36 is first identified as the platelet glycoprotein III b/IV, an 88 kDa heavily glycosylated transmembrane protein that belongs to 91 SR class B family. It consists of an extracellular domain flanked by 92 two transmembrane and two cytoplasmic domains. CD36 functions as a high-affinity receptor for ox-LDL, A domain located between 93 amino acids 155 and 183 of CD36 involves in ox-LDL binding. Other 94 ox-LDL binding sites have also been reported such as amino acids 95 28-93 and possibly 120-155. Binding of ox-LDL to CD36 leads to 96 endocytosis through a lipid raft pathway that is distinct from the 97 clathrin-mediated or caveolin internalization pathways. The patho- 98 genic role of ox-LDL in atherosclerosis largely depends on CD36. A 99 recent study revealed that plasma soluble CD36 correlates significant- 100 ly with markers of atherosclerosis, insulin resistance and fatty liver in 101 a nondiabetic healthy population [5]. Patients with acute coronary 102 syndromes exhibit a significant increase in CD36 expression in circu- 103 lating monocytes, which can be inhibited by a 6-month treatment of 104 atorvastatin [6]. Small molecules with anti-CD36 activity have been 105 shown to decrease postprandial hyperlipidemia and protect against 106 atherosclerosis [7]. In addition, the 573A allele of CD36 has a protec- 107 tive effect against atherosclerosis development while the 591T allele 108 is a cardiovascular risk factor [8]. On the other hand, Moore and col- 109 leagues reported that $apoE^{-/-}$ mice lacking CD36 or SR-A display in- 110 creased aortic sinus atherosclerotic lesion area and abundant 111 macrophage foam cells in the aortic intima despite reductions in peri- 112 toneal macrophage CE accumulation in vivo [9]. Moreover, clinical 113 studies show that patients with CD36 deficiency are associated with 114 severe and enhanced atherosclerotic diseases [10]. Therefore, the 115 role of CD36 as a proatherogenic mediator of ox-LDL uptake in vivo 116 needs to be reassessed. 117

CD36 is highly expressed in macrophages and its expression is regulated by multiple factors (Fig. 1). Recently, Inoue et al. reported that 119 astaxanthin (ASX), an oxygenated carotenoid (xanthophyll), significantly increases CD36 levels in peritoneal macrophages by stimulating 121 peroxisome proliferator-activated receptor- γ (PPAR γ) [11]. On the 122 other hand, curcumin, a potent antioxidant extracted from *Curcuma* 123 *longa*, induces a PPAR γ -independent CD36 overexpression through 124 upregulating nuclear erythroid-related factor 2(Nrf2) [12]. Additionally, 125 Gao et al. reported that palmitate increases CD36 expression in mono-26 cytes through the regulation of de novo ceramide synthesis [13]. Sup-127 plementation of the mushroom *Agaricus blazei* for 12 weeks markedly 128 elevates CD36 expression and plaque vulnerability in apoE^{-/-} mice, 129



Fig. 1. Regulation of CD36 and SR-A expression in macrophages. CD36 expression is induced by ASX and inhibited by TSIIA and quercitrin via PPARγ pathway. Palmitate increases CD36 levels while kaempferol, EM-1, squalene and walnut reduce its levels. Curcumin also upregulates CD36 expression through promoting Nrf-2 nuclear translocation but decreases SR-A protein expression via UPS. Berberine, Kv1.3 and TNF-α enhance SR-A levels, whereas MLPE and H₂S diminish its levels. RXR: retinoid X receptor.

Download English Version:

https://daneshyari.com/en/article/8313119

Download Persian Version:

https://daneshyari.com/article/8313119

Daneshyari.com